---
title: "Jyong Biotech files late-filing notice for its 2025 annual report on Form 20-F"
url: "https://aibio.space/news/jyong-biotech-files-late-filing-notice-2025-annual-report-form-20/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-04-29"
section: "Distress"
tickers: "NASDAQ:MENS"
source: "https://www.sec.gov/Archives/edgar/data/1954488/000121390026049070/ea0288284-nt20f_jyong.htm"
summary: "The company says it needs more time to finalize its audited financial statements and expects to file within 15 calendar days of the due date."
---

By the aibio.space news desk.

Sources

- [Jyong Biotech Ltd. NT 20-F (2026-04-29)](https://www.sec.gov/Archives/edgar/data/1954488/000121390026049070/ea0288284-nt20f_jyong.htm)

[MENS](https://aibio.space/companies/jyong-biotech/)

2026-04-29

# Jyong Biotech files late-filing notice for its 2025 annual report on Form 20-F

Tickers [MENS](https://aibio.space/companies/jyong-biotech/)

The company says it needs more time to finalize its audited financial statements and expects to file within 15 calendar days of the due date.

## Key facts

- **Company**: Jyong Biotech Ltd. (NASDAQ: MENS)

- **News type**: Distress

- **Primary source**: [Jyong Biotech Ltd. NT 20-F (2026-04-29)](https://www.sec.gov/Archives/edgar/data/1954488/000121390026049070/ea0288284-nt20f_jyong.htm)

*Old law books on library shelves. CC0, via rawpixel. The picture shows the field, not the companies named.*

Jyong Biotech Ltd. (Nasdaq: [MENS](https://aibio.space/companies/jyong-biotech/)) filed a Form NT 20-F on April 29, 2026, a notice that its annual report on Form 20-F for the fiscal year ended December 31, 2025 will be late.

The company said it is unable, without unreasonable effort or expense, to file within the prescribed period because of the additional time required to finalize its audited financial statements and other disclosures. It anticipates filing the Form 20-F on or before the 15th calendar day following the prescribed due date.

In the notice, the company answered yes to whether all other periodic reports required during the preceding 12 months have been filed. It answered no to whether it anticipates any significant change in results of operations from the corresponding period for the last fiscal year.

The forward-looking statements section lists, as a risk, changes to anticipated financial results once the independent registered public accounting firm completes its audit. The company lists its principal executive office in New Taipei City, Taiwan.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

MENS

Jyong Biotech Ltd.

NASDAQ · Taiwan

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/jyong-biotech-files-late-filing-notice-2025-annual-report-form-20/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Jyong Biotech files late-filing notice for its 2025 annual report on Form 20-F", 2026-04-29, https://aibio.space/news/jyong-biotech-files-late-filing-notice-2025-annual-report-form-20/